Sermorelin Side Effects: Safety Signals and Warnings
Sermorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions (redness, swelling), Facial flushing, and Headache. The main warning signals are Previously FDA-approved but discontinued (for commercial, not safety reasons), May not be effective in severe pituitary damage, and Monitor for excessive GH/IGF-1 elevation.
Direct Answer
Sermorelin has FDA-approved history (pediatric GHD) and Phase 2 human data on GH stimulation and body composition, though its short half-life limits practical utility compared to longer-acting GHRH analogs. Evidence is weaker than tesamorelin but stronger than most other GHRH analogs. For GHRH-pathway research, tesamorelin or CJC-1295 are better-evidenced alternatives depending on the endpoint.
- Evidence grade
- Level B
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- GH deficiency investigation, GHRH axis research, anti-aging GH stimulation
Reported Side Effects
- Injection site reactions (redness, swelling)
- Facial flushing
- Headache
- Dizziness
- Sleepiness
Warnings
- Previously FDA-approved but discontinued (for commercial, not safety reasons)
- May not be effective in severe pituitary damage
- Monitor for excessive GH/IGF-1 elevation
- Not for use with active malignancy
Known or Plausible Interactions
- Exogenous GH (use one or the other)
- Glucocorticoids (may blunt response)
- Thyroid hormones (hypothyroidism may reduce response)
- Other GH secretagogues (synergistic)
Regulatory Context
Previously FDA-approved (Geref, 1997), discontinued by manufacturer in 2008. Still available through compounding pharmacies by prescription. Not a controlled substance. FDA placed restrictions on compounding in 2023 but later reversed some decisions.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Growth Hormone Stimulation (Level B), Body Composition (Adults) (Level C), and Sleep Quality (Level C) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Sermorelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/sermorelin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.